BioMarin Pharmaceutical Inc said on Thursday the U.S. Food and Drug Administration had rejected the company's drug to treat a rare muscle-wasting disorder.
The drug, Kyndrisa, was expected to be the first treatment in the United States for Duchenne muscular dystrophy (DMD) - a disorder that affects one in 3,600 newborn boys and causes rapid muscle degeneration.
The rejection comes after a panel of independent advisers to the FDA indicated that efficacy data on the drug was not persuasive enough for an approval.
The drug, Kyndrisa, was expected to be the first treatment in the United States for Duchenne muscular dystrophy (DMD) - a disorder that affects one in 3,600 newborn boys and causes rapid muscle degeneration.
The rejection comes after a panel of independent advisers to the FDA indicated that efficacy data on the drug was not persuasive enough for an approval.
